Benufutamab
Benufutamab Basic information
- Product Name:
- Benufutamab
- Synonyms:
-
- Benufutamab
- Research Grade Benufutamab (DHA29101)
- Research Grade Benufutamab
- Benufutamab (anti-TNFRSF10B)
- CAS:
- 2109730-69-8
- MW:
- 0
- Mol File:
- Mol File
Benufutamab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Benufutamab Usage And Synthesis
Uses
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1].
in vivo
Benufutamab (GEN1029; HexaBody-DR5/DR5; 0.5-2 mg/kg; i.p.; once a week; for 9 weeks) shows significant antitumor activity in PDX models for colorectal cancer[2].
| Animal Model: | Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells[2] |
| Dosage: | 0.5 mg/kg, or 2 mg/kg |
| Administration: | i.p.; once a week; for 9 weeks |
| Result: | Showed significant antitumor activity. |
References
[1] Hilma J van der Horst, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172. DOI:10.1182/bloodadvances.2020003731
[2] Marije B Overdijk, et al. Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol Cancer Ther. 2020 Oct;19(10):2126-2138. DOI:10.1158/1535-7163.MCT-20-0044
BenufutamabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com